Aprepitant, Palonosetron and Dexamethasone Antiemetic Therapy Evaluation trial in germ cell tumor (APDATE)
Not Applicable
Recruiting
- Conditions
- Germ cell tumor
- Registration Number
- JPRN-UMIN000008110
- Lead Sponsor
- Department of Urology, Sapporo Medical University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Male
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1. Uncontrollable complications 2. Brain metastasis 3. Active convulsive disease 4. Plural effusion or ascites requiring puncture 5. Obstruction of the gastric outlet or ileus 6. Vomiting or severe nausea before the chemotherapy 7. Anaphylaxis against 5-HT3 receptor inhibitors, aprepitant or dexamethasone 8. Disapproval of contraception 9. History og aprepitant or palonostron 10. Participation of other clinical trials of antiemetics
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Complete response
- Secondary Outcome Measures
Name Time Method Conplete control (no emetic episodes, no rescue medication use and no more than mild nausea), adverse events